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Atypical angiogenesis is one of the major symptoms of severe eye diseases, including corneal neo-
vascularization, and the complex nature of abnormal vascularization requires targeted methods with
high biocompatibility. The targeting of VEGF is the most common approach for preventing angiogenesis,
and the LPPR peptide sequence is known to strongly inhibit VEGF activity by binding to the VEGF re-
ceptor neuropilin-1. Here, the LPPR epitope is presented on a peptide amphiphile nanofiber system to
benefit from multivalency and increase the anti-angiogenic function of the epitope. Peptide amphiphile
nanofibers are especially useful for ocular delivery applications due to their ability to remain on the site
of interest for extended periods of time, facilitating the long-term presentation of bioactive sequences.
Consequently, the LPPR sequence was integrated into a self-assembled peptide amphiphile network to
increase its efficiency in the prevention of neovascularization. Anti-angiogenic effects of the peptide
nanofibers were investigated by using both in vitro and in vivo models. LPPR-PA nanofibers inhibited
endothelial cell proliferation, tube formation, and migration to a greater extent than the soluble LPPR
peptide in vitro. In addition, the LPPR-PA nanofiber system led to the prevention of vascular maturation
and the regression of angiogenesis in a suture-induced corneal angiogenesis model. These results show
that the anti-angiogenic activity exhibited by LPPR peptide nanofibers may be utilized as a promising
approach for the treatment of corneal angiogenesis.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Angiogenesis is the formation of new blood vessels from pre-
existing networks and is tightly regulated through the activation
of endothelial cells, local degradation of the extracellular matrix
and vascular basement membranes, and stabilization of newly
formed vessels through the proliferation and migration of the
native cell population [1]. Endothelial cell activation is critical for
the modulation of this process and is determined by the positive
(angiogenic) and negative (anti-angiogenic) regulators of angio-
genesis, including VEGF, aFGF and bFGF [2]. Abnormalities in the
production of these growth factors and their downstream elements
may result in excessive or insufficient blood vessel formation,, moguler@unam.bilkent.edu.
).potentially interfering with the function of affected tissues.
Pathological angiogenesis occurs in many disorders, including
corneal neovascularization, which causes visual impairment
through the loss of ocular transparency [3]. Vascular endothelial
growth factor (VEGF) and its receptors have been found to be sig-
nificant modulators of angiogenesis, and their inhibition is an
effective means of corneal neovascularization treatment. Bev-
acizumab, a clinically approved drug, is a recombinant humanized
monoclonal IgG1 antibody that binds to and inhibits the biological
activity of human VEGF both in vitro and in vivo [4]. However, while
bevacizumab therapy has been shown to facilitate the regression of
corneal neovascularization in animal studies and clinical reports, its
effectiveness is limited by safety issues and the recurrence of
neovascularization in certain cases [5]. High costs, difficulties of
manufacturing and short half-lives are further disadvantages of
bevacizumab and other antibody drugs [6]. Therefore, new thera-
peutics and formulations capable of eliminating these deficiencies
are urgently needed.
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tential for inhibiting the activity of angiogenic factors. Self-
assembling peptide amphiphile molecules consist of a hydrophilic
head group containing bioactive epitopes and b-sheet forming se-
quences, which is chemically conjugated to a hydrophobic tail re-
gion that further assists in the assembly process [7]. They have a
wide range of applications, such as tissue engineering, regenerative
medicine, diagnostic tools, drug delivery and functional bio-
materials [8e10]. They are favorable over proteins and other small
molecules due to their stability and ease of preparation and puri-
fication. In addition, several reports have recently shown that
peptide systems can be used as angiogenesis inhibitors [11e13].
The LPPR peptide sequence has previously been identified by
the phage display technique and was shown to bind specifically to
the VEGF receptor, neuropilin-1 (NRP-1) [14]. This binding strongly
inhibits the activation of NRP-1 by VEGF165, and the LPPR sequence
is responsible for 75% of this inhibition [15]. In addition, the peptide
was able to significantly decrease tumor growth through the inhi-
bition of angiogenesis in an in vivo breast cancer model, while a
similar peptide sequence, D(LPR), exhibited promising results for
the treatment of retinopathy of prematurity [16,17]. Since the LPPR
peptide sequence is essential for the inhibition of VEGF activity, we
utilized this peptide sequence on a self-assembled peptide
amphiphile nanofiber system to increase epitope presentation and
create a highly effective anti-angiogenic agent.
The Lauryl-VAAGKKGLPPR-Am peptide amphiphile molecule
was designed and synthesized to form a b-sheet containing su-
pramolecular structure, thereby increasing its solubility in water
and presenting the functional epitope on a nanofiber system. The
self-assembly process, secondary structure and cellular localization
of the peptide nanofibers were characterized in detail. The capacity
of the peptide nanofiber formulation to inhibit blood vessel for-
mation was then evaluated by using in vitro angiogenesis, scratch
healing and tube formation assays. In addition, the effect of nano-
fibers was studied in an in vivo suture induced corneal neo-
vascularization model. The efficiency of the bioactive PA nanofibers
was found to be comparable to the commercially available drug
bevacizumab and superior to the soluble peptide formulation.
2. Material and methods
2.1. Materials
All 9-fluorenylmethoxycarbonyl (Fmoc) and tert-butoxycarbonyl
(Boc) protected amino acids, [4-[a-(20,40-dimethoxyphenyl) Fmoc-
aminomethyl]phenoxy]acetamidonorleucyl-MBHA resin (Rink
amide MBHA resin), and Fmoc-Asp(OtBu)-Wang resin were pur-
chased from NovaBiochem. 2-(1H-Benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) was purchased
from ABCR. Antibodies were purchased from Abcam and Millipore.
Matrigel™ (growth factor reduced) was purchased from BD Bio-
sciences (356230), Live-Dead viability assay kit from Thermo Fisher
Scientific (L3224) and ELISA-based BrdU proliferation assay kit from
Roche (11647229001). All other materials were obtained from Invi-
trogen, Fisher, Merck, Alfa Aesar, and Sigma-Aldrich. All materials
were analytical grade.
2.2. Peptide synthesis and nanofiber formation
Peptide amphiphile (PA) molecules used in this study were
synthesized by solid phase peptide synthesis. Rink amide MBHA
resin (for Ac-LPPR-Am, LPPR-PA, scrambled-PA and K3-PA) and
Fmoc-Glu(OtBu)-Wang resin (for E-PA) were used as solid support.
Coupling reactions of amino acids were performed with 2 equiva-
lents of Fmoc protected amino acid, 1.95 equivalents of HBTU and 3equivalents of N,N-diisopropylethylamine (DIEA) in DMF for 3 h.
Fmoc removals were performed with 20% piperidine/dime-
thylformamide (DMF) solution for 20 min.
All peptides were cleaved from the resin using a mixture of
trifluoroacetic acid (TFA), triisoproplysilane (TIS), and water at a
ratio of 95: 2.5: 2.5 for 2.5 h. Excess TFA was removed by rotary
evaporation and the sample was triturated with ice-cold diethyl
ether. Diethyl ether was then removed and the pellet was dissolved
in water for freeze-drying. Peptide samples were analyzed and
purified by reverse phase preparative HPLC on an Agilent 6530
Accurate-Mass Q-TOF LC/MS equipped with an Agilent 1200 HPLC.
The bioactive LPPR-PA nanofiber was formed bymixing LPPR-PA
and E-PA at 1:1 molar ratio, while the non-bioactive K3-PA/E-PA
control nanofiber was similarly formed by mixing K3-PA and E-PA
at 1:1 molar ratio. Scrambled-PA was also mixed with E-PA at 1:1
molar ratio. Net charges were þ1 for all nanofibers and LPPR pep-
tide (Fig. S1). Peptide mixtures and solutions were adjusted to pH
7.4 with HCl or NaOH prior to use.
Circular dichroism (CD) measurements were carried out at
100 mM peptide concentrations in water and a 1-mm path length
quartz cuvette. Peptides were vortexed to ensure mixing and the
pH was adjusted with HCl or NaOH to 7.4. Measurements were
acquired at room temperature at 500 nm/min scanning speed,1 nm
bandwidth and 0.1 nm data pitch using a J-815 Jasco spectropho-
tometer. The 190e300 nm spectral regions were monitored for the
analysis of the secondary structures of peptides.
Transmission electron microscopy (TEM) and scanning trans-
mission electron microscopy (STEM) samples were prepared at a
final concentration of 100 mM of mixtures of positively and nega-
tively charged peptides in water. 5 mL of samples were cast onto
TEM grids and incubated for 5min. Samples were then stainedwith
2 wt % uranyl acetate solution and washed twice with a drop of
MilliQ water. Imaging was performed by using a FEI Tecnai G2 F30
TEM with electron energy of 100 kV.
Sample solutions for AFM were dropped on a glass surface and
mixed by pipetting. 25 mL of 100 mM scrambled-PA and equimolar
concentrations of E-PA were used for sample preparation. Peptides
were dissolved in water and solutions were adjusted to pH 7.4 for
nanofiber formation. After 30 s, excess solution was removed using
dust-free tissue paper, and the precipitated PA networks were air-
dried in a convection oven. Contact mode atomic force micro-
scopy (AFM) was performed using a MFP-3D AFM (Asylum
Research, US). Images were taken in air using a SiNi tip with a
nominal spring constant of 0.2 N/m, under a scan rate of 0.5 Hz and
at a resolution of 512  512.
2.3. In vitro cell culture studies
Human umbilical vein endothelial cells (HUVECs) were cultured
in a humidified, 37 C, 5% CO2 incubator using 75 cm2 polystyrene
cell culture flasks containing low glucose Dulbecco's modified Ea-
gle's medium (DMEM) supplemented with 10% fetal bovine serum
(FBS, Gibco), 1% penicillin/streptomycin (P/S) and 2 mM L-
glutamine.
Viability of HUVECs on soluble nanofibers was tested using Live-
Dead viability assay. HUVECs were seeded in 96-well plates at a
density of 2  103 cells/well. After 24 h of peptide incubation, cells
were stained with Calcein AM and ethidium homodimer reagents
at 2 mM and 4 mM concentrations, respectively. After 30 min of
incubation, cells were observed under fluorescence microscope,
and live and dead cells were counted by using ImageJ (NIH) soft-
ware. Viability was assessed by calculating the ratio of live cells to
total cell numbers. Experiments were carried out with n ¼ 4 and
images were taken from 5 different locations per well.
Cell proliferation was evaluated using a colorimetric ELISA-
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to the manufacturer's instructions. Briefly, HUVECs were seeded
onto a 96-well plate at a density of 5  103 cells/well. Cells were
subsequently incubated with VEGF (100 ng/mL) in the presence or
absence of peptides for 24 h at 37 C, and the extent of BrdU
incorporation was quantified by spectrophotometry. Each group
was tested at least in triplicate, and the assays were repeated a
minimum of three times. The IC50 of cell proliferation was calcu-
lated by taking untreated cells as maximum and using GraphPad
program.
For in vitro scratch wound healing assay, HUVECs were incu-
bated with 100 mM of peptides for 24 h. 5  104 HUVECs per well
were seeded in 24-well plates and grown into a monolayer culture
with 100% confluency. After scratching through themonolayer with
a pipette tip, wound closure was visually monitored with a Zeiss
Axio Scope Inverted Microscope and the ability to recover from
wounds (% closure) was quantified using proprietary software
associated with the microscope system.
In vitro angiogenesis/tube formation assays were performed as
previously described [18]. Briefly, the impact of peptide hydrogel
formulations on in vitro angiogenesis was tested using HUVECs
(4  104 cells/well) seeded in Matrigel™ (50 mL) coated chambered
slides (96-well) containing 100 mM of peptide samples, with TCP
utilized as control. HUVECs were incubated at 37 C for approxi-
mately 6 h, and capillary-like structures were imaged using a Zeiss
Axio Scope Inverted Microscope.2.4. Animal models
All procedures involving animal experiments were approved by
Gazi University Animal Ethics Committee. Suture-induced corneal
angiogenesis was used as the neovascularization model, since the
cornea is normally an avascular tissue and, therefore, serves as an
ideal in vivo model for studying the effects of angiogenesis.
Adult male SpragueeDawley (SD) rats were exposed to 12 h
light-dark cycles and fed a standard laboratory diet with food and
water provided ad libitum. All rats (weighing 200e220 g and aged 8
weeks) were deeply anesthetized prior to surgery. 10-0 nylon su-
tures were placed at 1e1.5 mm distance from the temporal limbus
of the cornea, and the time of suture placement was considered as
day 0. The suturing operationwas performed on only one eye, while
the other eye of the animal was left as internal control. Following
suture placement, rats were randomized to five groups: Group I
(n ¼ 4) treated with Ac-LPPR-Am, Group II (n ¼ 4) treated with K3-
PA/E-PA, Group III (n ¼ 4) treated with LPPR-PA/E-PA, Group IV
(n ¼ 4) treated with bevacizumab and Group V (n ¼ 4) without any
treatment (suture-only group). Corneas were observed for 7 days
following the operation to ensure that the suture is successful in
stimulating corneal neovascularization and only animals exhibiting
neovascularization were subjected to further treatment. LPPR-PA
nanofibers and control peptides were delivered to rat corneas by
subconjunctival injection (1 cc of 1 mM peptides) on day 7. Simi-
larly, group IV received a subconjunctival injection of 0.1 cc bev-
acizumab (Avastin®) at a concentration of 25 mg/mL on day 7.
Corneal images were taken using a surgical microscope on day
0 (operation day), day 7 (injection day), and day 14. Images were
used to measure the corneal surface covered with neovascular
vessels. To increase reproducibility, the entire surgery process was
performed by a single investigator (B.A.) for every animal. Pupils
were dilated with drops of tropicamide 0.5% (Tropamid®) prior to
each imaging session [19]. Neovascularization of each cornea was
evaluated by an examiner who was blind to the treatment groups.
Corneas were then removed and processed for further histological
analysis.2.5. Histological analysis
On day 14, all rats were sacrificed and their eyes were fixed with
10% formalin and embedded in paraffin. Tissue sections (5 mm),
which were taken with a Leica microtome, were deparaffinized in
xylene, rehydrated through graded alcohols to distilled water, and
stainedwith hematoxylin and eosin (H&E). Endogenous peroxidase
was inactivated with 3% hydrogen peroxide for 10 min at room
temperature, and nonspecific binding sites were blocked with 10%
normal goat serum for 2 h. Antigens were then detected through
indirect binding using their respective primary antibodies and
HRP-conjugated secondary antibodies. Serial sections were
immunolabeled with anti-von Willebrand factor antibody (1:400
dilution; ab6994, Abcam), and a secondary antibody (1:500 dilu-
tion; ab6721) to evaluate neovascularization. Sections were
developed in 3,3’-diaminobenzidine (DAB) and counterstained
with hematoxylin.
The number of blood vessels was counted from at least 6
randomly selected fields in each section. Sections were immuno-
labeled with anti-vonWillebrand factor antibody and quantified by
two independent observers under 200 magnification. Quantifi-
cations were performed by the ImageJ analysis system to calculate
the number of vessels in each field.
2.6. Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.
One-way ANOVAwas used to compare the differences between the
groups and Bonferroni's multiple comparisons test was used for
post-hoc correction. Error bars indicate ± SEM (standard error of
mean). At least three independent repeats were performed for each
in vitro experiment, with a minimum of n ¼ 3 for each repeat.
In vivo experiments were performed at a minimum of n ¼ 4.
3. Results
3.1. Synthesis and characterization of PAs
In this study, the LPPR peptide sequence was conjugated to a b-
sheet forming peptide amphiphile molecule to create an effective
anti-angiogenic nanofiber system. The well-ordered nanofibrous
morphology of this self-assembled peptide system can increase the
presentation of the bioactive sequence to the VEGF receptor NRP-1,
thereby blocking VEGF's angiogenic effect through competitive
exclusion. The soluble LPPR peptide was also synthesized in addi-
tion to the amphiphilic form. Lauryl-VVAGKKGLPPR-Am (LPPR-PA)
wasmixedwith lauryl-VVAGE (E-PA) at a 1:1 ratio to form bioactive
LPPR-PA nanofibers, while lauryl-VVAGKKK-Am (K3-PA) was mixed
1:1 with E-PA to form non-bioactive control nanofibers. Scrambled
peptide amphiphile form of LPPR-PA was designed as lauryl-
VVAGKKGPPLR-Am. Since the presence of arginine residue on the
surface has previously been shown to be critical for neuropilin-1
affinity, we replaced leucine with proline amino acids in scram-
bled variant in order to present arginine residues on nanofiber
surface. All PAmixtures have a final charge ofþ1, resulting from the
respective charges of E-PA (at 2), and LPPR-PA, scrambled-PA and
K3-PA (at þ3) (Fig. S1). Chemical structures of all peptides are given
in Fig.1A. Solid-phase peptide synthesis was used in the production
of all peptide molecules used, and the peptide products were
characterized by LC-MS and purified with preparative HPLC
(Fig. S2).
Circular dichroism (CD) spectroscopy was utilized to analyze the
secondary structures associated with formation of nanofibers by
peptide amphiphiles and their mixtures [20]. CD results showed
that the nanofibrous structures formed by PA molecules contained
Fig. 1. Self-assembled peptide amphiphile (PA) nanofibers at pH 7.4. Chemical structures of LPPR-PA, LPPR, E-PA and K3-PA are provided (A). TEM images of the LPPR-PA nanofibers
and STEM showing control nanofibers, which were stained with uranyl acetate (scale bar ¼ 50 mm) (B). LPPR-PA, scrambled and control nanofibers formed b-sheet secondary
structures analyzed by CD measurements (C). Peptides were dissolved in water and the pH was adjusted with NaOH for TEM, STEM and CD measurements.
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around 200 nm and minima at around 220 nm (Fig. 1C). TEM and
STEM were performed to investigate the morphology of the self-
assembled nanostructures in solution and confirmed that the
peptide formulations exhibited nanofibrous morphology (Fig. 1B).
Both control and LPPR-PA nanofiber structures were 10e20 nm in
diameter and up to several micrometers in length. TEM imaging of
the non-amphiphilic LPPR peptide did not yield observable results
due to its lack of nanostructure formation. AFM imaging of the
scrambled peptide system also revealed a nanofibrous structure,
with diameters in the 10e20 nm range (Fig. S3).
The effect of peptide nanofibers on cellular viability of endo-
thelial cells was analyzed with Live/Dead assay, which demon-
strated that LPPR, control, scrambled-PA and LPPR-PA nanofibers
did not alter the viability of HUVECs at a concentration of 100 mM
(Fig. S4A). Cell survival rate of all treatment groups were similar to
those on tissue culture plate (TCP) after 24, 48 and 72 h of incu-
bation (Fig. S4B). Even when toxicity assay was performed for
higher doses of LPPR-PA nanofibers (up to 1024 mM), no toxicity was
observed on HUVECs (Fig. S4C). Overall, these results indicated
biocompatibility of control and LPPR-PA nanofibers.
3.2. LPPR-PA/E-PA treatment reduces endothelial cell proliferation,
migration and angiogenic tube formation
Cell proliferation, migration and tube formation assays were
performed to systematically assess the anti-angiogenic effect ofLPPR-PA nanofibers on endothelial cells. Angiogenic regulators,
such as VEGF stimulate the proliferation of endothelial cells during
blood vessel formation; consequently, the proliferation of HUVECs
was evaluated in the presence of VEGF to determine whether the
peptide networks were able to disrupt the VEGF/NRP-1 interaction.
We demonstrated that LPPR-PA nanofibers inhibited cell prolifer-
ation in a dose-dependent manner and with an IC50 of 107 mM,
suggesting that the sequence is able to interfere with endothelial
cell growth when incorporated into a peptide nanofiber material
(Fig. 2B). Tournaire and colleagues have previously shown that
ATWLPPR peptide treatment caused 60% inhibition in vascular
endothelial cell proliferation at a concentration of 420 mM [14].
Here, 100 mM of LPPR peptide did not cause any effect on the pro-
liferation of HUVECs, while the PA form of this sequence was much
more effective in mediating the inhibition of cell proliferation. The
inhibitory effect of LPPR-PAwas also found to be sequence-specific,
since control and scrambled-PA nanofiber did not show any activity
at the same concentration (Fig. 2A).
The migration of endothelial cells is an important step of
angiogenesis and can be evaluated in vitro by scratch wound
healing assay, where a gap is created on a cellular monolayer and its
closure is measured to determine the rate of the surrounding cells
migrating into the wound [21]. The inhibitory activity of LPPR-PA
nanofibers was determined by analyzing the wound closure per-
centage of HUVECs after 24 h (Fig. 3). Migration was found to be
significantly lower than control in HUVECs treated with LPPR-PA
nanofiber in the presence of VEGF. In addition, control nanofibers
Fig. 2. The quantification of inhibitory effects of LPPR-PA nanofiber on HUVECs. Effect of 100 mM peptide or peptide nanofibers and 0.25 mM or 2.5 mM of bevacizumab treatment
on proliferation were investigated with ELISA-based BrdU proliferation assay (A). HUVECs were treated with different concentrations (0e1024 mM) of peptides for 24 h to assess IC50
calculation of LPPR-PA by using an ELISA based-BrdU assay (B). Data are presented as means ± SEM, and one-way ANOVA analysis was performed at *p < 0.05, ***p < 0.001 and
****p < 0.0001.
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(Fig. 3B). Consistent with the proliferation assay results, scratch
wound closure measurements demonstrated that VEGF-mediated
angiogenesis was markedly blocked by LPPR-PA nanofibers.
During angiogenesis, endothelial cells proliferate and migrate
toward an angiogenic growth factor stimulus, and eventually form
lumen-bearing tubes to conduct the blood flow. A Matrigel™ tube
formation assay was therefore performed to investigate the anti-
angiogenic properties of peptide formulations by quantifying
their ability to prevent the formation of endothelial tubes. Matri-
gel™ contains a mixture of basement membrane components that
stimulate endothelial cells to form capillary-like hexagonalFig. 3. Anti-angiogenic peptide treatment inhibits cell migration. Representative bright field
migration was imaged after 24 h (A). TCP is considered as a positive control (after 24 h, 100%
calculated with Image J (B). Control, scrambled and LPPR-PA nanofiber treatment significant
**p < 0.01, and ***p < 0.001; images were taken at 100 magnification.structures, and is often preferred over other in vitro assays because
of its ease of use and the ability to provide a rapid and quantitative
assessment of angiogenesis [22]. Here, growth factor-reduced
Matrigel™ was used with 100 mM of VEGF to investigate VEGF-
induced tube formation. Angiogenesis assay showed that only
non-treated TCP control had well-ordered tube structures (Fig. 4A).
Furthermore, tube length measurements were performed to
compare the efficacy of treatments in inhibiting angiogenesis. LPPR
peptide, control nanofiber, LPPR-PA nanofiber and bevacizumab
treatments inhibited tube length by 67.3 ± 7.19%, 73.6 ± 7.68%,
93.08 ± 6.19% and 89.8 ± 10.1% compared toTCP, respectively. These
data indicated that peptide treatments in general reduced theimages of HUVECs treated with peptides or TCP control, they were scratched and cell
closure). Wound margins were determined (white line) and closure percentages were
ly suppressed cellular migration One-way ANOVA analysis was performed at *p < 0.05,
B. Senturk et al. / Biomaterials 107 (2016) 124e132 129tubular assembly of endothelial cells, but LPPR-PA nanofiber
treatment caused the most significant inhibition of tube lengths
(Fig. 4). The inhibition rate was as strong as bevacizumab treat-
ment, suggesting that LPPR-PA nanofiber treatment was able to
suppress VEGF-induced angiogenesis in vitro. In contrast, the
scrambled nanofiber did not exhibit any capacity for the inhibition
of angiogenesis beyond the LPPR-PA and control nanofibers.3.3. The subconjunctival injection of LPPR-PA nanofibers inhibits
suture-induced corneal neovascularization
After demonstrating the anti-angiogenic activity of LPPR-PA
nanofibers in vitro, we next investigated the in vivo efficacy of
peptide nanofibers using a suture-induced corneal angiogenesis
model. As the scrambled PA sequence did not exhibit a substantial
anti-angiogenic effect, it was not included in in vivomeasurements
and a non-bioactive control nanofiber was used instead. Pre-
liminary studies showed that neovascularization began to occur
near the corneal suture on day 1 or 2 after surgery and had
advanced greatly by day 7. Consequently, subconjunctival injection
of peptides was performed on day 7 to better reflect the clinical
presentation of corneal neovascularization, which is typically
diagnosed only after advanced neovascularization.
The in vivo anti-angiogenic activity of LPPR-PA nanofibers was
evaluated through the measurement of blood vessel growth areas.
Corneal neovascularization was induced in all treatment groups
with a similar vessel growth area on day 7 (Fig. 5B). Representative
images of corneas on day 14 and schematic illustration of in vivo
experiments are shown in Fig. S5. The subconjunctival injection ofFig. 4. LPPR-PA nanofiber treatment suppressed tube formation in a Matrigel™-based angio
Matrigel™ and imaged after 6 h of incubation. Images represent impact of the peptide an
indicates formation of capillary-like structures. Tube lengths were measured from images
analysis, one-way ANOVA was performed at **p < 0.01, ***p < 0.001 and ****p < 0.0001. ScLPPR-PA nanofiber significantly inhibited corneal neo-
vascularization in rats compared to other treatment group on day
14 (Fig. 5). Moreover, the efficacy of the peptide nanofiber was
higher than the LPPR peptide and bevacizumab: Bevacizumab
showed a 51.2% inhibition of corneal neovascularization in our rat
model, while LPPR-PA nanofiber treatment resulted in around
81.3% inhibition relative to untreated controls. The efficacy of
subconjunctival bevacizumab treatment in this model was similar
to its efficacy in humans, suggesting that LPPR-PA nanofiber may be
a better alternative for corneal neovascularizaiton therapy [23].
However, further studies are required to compare the safety of
nanofiber injections and conclusively demonstrate the advantage
of anti-angiogenic peptides for the treatment of corneal
neovascularization.
The effects of the anti-angiogenic peptide nanofibers on new
vessel formation were further characterized through von Wille-
brand factor staining on day 14 after surgery. The total number of
vessels was calculated from both central and peripheral areas of the
corneal surface. Histological and quantitative analyses of the cornea
revealed that LPPR-PA nanofiber treatment led to a significant
reduction in the number of blood vessels compared to untreated
control (Fig. 6). Although corneal neovascularization was not
completely regressed, only a small number of vessels had remained
in the peripheral area after a single injection of LPPR-PA. These data,
in tandemwith vessel growth area calculations, indicate that VEGF
suppression plays an important role in the inhibition of corneal
angiogenesis, and that LPPR-PA treatment can effectively reduce
corneal neovascularization through this process.genesis assay. HUVECs with and without 100 mM of peptide treatment were seeded on
d peptide nanofibers on angiogenesis (A). White dashed lines in no treatment group
after 6 h of incubation using Image J and quantification is given in B. For statistical
ale bars are 100 mm.
Fig. 5. Inhibitory effect of LPPR-PA nanofibers on suture-induced corneal neovascularization in rats. Images of corneas treated with bevacizumab and LPPR-PA nanofiber were taken
at day 0, 7 and 14 (A). Suture induction resulted in intensive neovascularization, which had similar vessel growth area on each group at day 7 (B). Reduced neovascularization was
detected in LPPR-PA nanofiber-injected rats compared to other treatment groups. Quantification of vessel areas showed that the most significant inhibition of vascularization is
found in the anti-angiogenic nanofiber treated group (B). One-way ANOVA analysis was performed at *p < 0.05, **p < 0.01, and ***p < 0.001.
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Disruption of aberrant VEGF signaling is the most common
strategy for the treatment of corneal neovascularization, which
aims to facilitate the regression and elimination of abnormal blood
vessels. Since the angiogenic activity of VEGF is mediated by its
receptors, the blocking of receptor-ligand interactions is a prom-
ising approach for anti-VEGF therapies. In this study, the LPPR
sequence was incorporated into a peptide amphiphile sequence
capable of self-assembling into a transparent and stable nanofiber
matrix [24]. The LPPR-PA molecule contains hydrophilic head and
hydrophobic tail regions, which mediate self-assembly through
both electrostatic interactions and hydrophobic collapse to form
ordered structures. The mixing of LPPR-PA with oppositely charged
E-PA formed stable nanofibers. TEM and CD analyses of peptide
amphiphiles confirmed that the PA molecules formed b-sheet-rich
nanofiber structures (Fig. 1). The bioavailability and biocompati-
bility of peptide assemblies are critical for designing nano-
therapeutic systems, and factors such as concentration, hydrogen
bonding and charge may severely affect the biocompatibility of
peptides [25,26]. Consequently, the biocompatibility of the PA
nanofibers was investigated using Live-Dead assay and both LPPR-
PA and controls were found not to be toxic to cells at a concen-
tration of 100 mM (Fig. 2).
Anti-angiogenic properties of LPPR-PA nanofibers were inves-
tigated in vitro by cell proliferation, migration and tube formation
assays. Effects of LPPR-PA nanofibers on angiogenesis were
compared to LPPR peptide, control and scrambled PA nanofibers.
LPPR-PA nanofiber had significant inhibitory effect on cell prolif-
eration in a dose-dependent manner. In contrast, the soluble LPPR
peptide inhibited cellular growth only to a lesser extent, possibly
because the nanofibrous architecture of peptide amphiphile sys-
tems improves the efficiency of the bioactive sequence by medi-
ating its presentation to NRP-1. In addition, resistance of nanofiber
systems to proteolytic degradation may contribute to theirefficiency [27,28]. The binding of VEGF to NRP-1 was reported to be
essential for VEGF-induced cell migration; consequently, an in vitro
scratch wound healing assay was performed to examine the role of
the LPPR sequence on cell migration [29,30]. LPPR-PA nanofiber
treatment was found to significantly inhibit wound closure by
HUVECs in 24 h, suggesting that the bioactive nanofibers are able to
effectively prevent VEGF-induced cellular migration (Fig. 3).
Although migration was markedly inhibited by the LPPR-PA
nanofiber, the control nanofiber also surprisingly exhibited a sup-
pressive effect compared to TCP (Fig. 4). This effect may have been
caused by the multivalent presentation of charged residues on
peptide nanofibers, which can limit the migration of endothelial
cells and allow control nanofibers to display some measure of anti-
angiogenic effect. However, peptide sequence is essential for anti-
angiogenic activity since LPPR-PA nanofiber was able to inhibit
migration more efficiently than the scrambled-PA nanofiber.
HUVECs form capillary-like tubes when stimulated with
angiogenic factors, and this property can be used to assess the anti-
angiogenic properties of a broad variety of materials [31]. The
angiogenesis assay demonstrated that peptide nanofiber treatment
significantly reduced tube formation in the presence of VEGF,
exhibiting a suppressive effect comparable to the commercially
available drug bevacizumab (Fig. 4). Control nanofibers also
exhibited an inhibitory effect on tube formation, which normally
requires the clustering of endothelial cells and may have been
blocked by the prevention of cellular migration induced by control
peptides. This result reveals that charge and structural properties
also had effects on bioactivity of thematerial. However, comparison
of activity of LPPR-PA on angiogenesis with control and scrambled-
PA showed that the sequence itself plays an important role.
While peptide sequences (including the LPPR motif) have pre-
viously been reported to inhibit endothelial cell proliferation and
tube formation; peptide nanofibers described in the present study
were observed to inhibit corneal angiogenesis to a greater extent
than the soluble peptides, potentially because of the ability of well-
Fig. 6. LPPR-PA nanofiber treatment inhibits corneal neovascularization. Histological (A) and quantitative (B) analysis of the cornea revealed that all treatments led to a significant
reduction in the number of blood vessels when compared with the suture-only control. One-way ANOVA analysis was performed at *p < 0.05. Representative images of von
Willebrand Factor (brown) staining of corneal tissue sections and hematoxylin-blue counterstaining of nuclei (blue). Arrows show blood vessels on corneal stroma. (For inter-
pretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
B. Senturk et al. / Biomaterials 107 (2016) 124e132 131organized peptide nanofibers to present their bioactive sequences
in a coordinated and multivalent manner [14,17]. In addition,
peptide network treatment resulted in a substantially greater
reduction in blood vessel numbers compared to the commercially
available drug bevacizumab, suggesting that the LPPR-PA nanofiber
systemmay be utilized as a novel therapeutic agent against corneal
neovascularization.
The efficacy of nanofiber peptide treatment in cornea was
investigated in vivo by using suture-induced angiogenesis model.
This model is well-established in rats, sees widespread use in
neovascularization research and has been shown to provide a
quantitative and reproducible assessment of in vivo angiogenesis
[32e34]. In vivo studies showed that LPPR-PA reduced corneal
neovascularization more effectively than LPPR peptide and bev-
acizumab (Fig. 5). This result was supported through the quantifi-
cation of the number of blood vessels by vonWillebrand staining of
corneal tissue sections. While we have demonstrated that LPPR-PA
nanofibers inhibit angiogenesis in vitro and reduce corneal vascu-
larization in vivo, further studies are necessary to confirm the
effectiveness of the material as a therapeutic agent.
It is well-known that the maintenance of the avascular and
transparent structure of the cornea depends strongly on the bal-
ance between angiogenic and anti-angiogenic factors, and that
VEGF plays a crucial role in this process. Due to its strong and highlyspecific affinity to VEGF, LPPR-PA might be utilized for the treat-
ment of excessive vascularization associated with this growth fac-
tor. However, in disorders involving multiple growth factors,
treatment with other anti-angiogenic molecules, such as anti-IGF-1
(Insulin-like growth factor-1), anti-PDGF (platelet derived growth
factor), PEDF (pigment epithelium-derived factor) and endostatin,
may be combined with LPPR-PA application for better prognosis.
5. Conclusion
Corneal neovascularization is associated with severe visual
impairment and its rapid and effective treatment is of great
importance for restoring the sight of the affected. The peptide
nanofiber system described in the present study is able to reduce
corneal blood vessel areas even after extensive vascularization had
already taken place, and was as effective as a commercial agent in
this capacity. Comparison of LPPR-PA nanofiber and LPPR peptide
treatments suggested that the nanofiber form is more effective in
reducing angiogenesis than the soluble peptide, possibly because of
the ordered organization of the bioactive sequences in peptide
nanofibers. A sustained release effect may also be responsible for
this phenomenon, as the soluble peptide is more susceptible to
proteolytic action and may be removed from the cornea with time.
Overall, data from a variety of in vitro and in vivo experimental
B. Senturk et al. / Biomaterials 107 (2016) 124e132132approaches suggest that LPPR-PA nanofibers effectively inhibit
endothelial cell proliferation and migration, aberrant capillary
formation and neovascularization in the eye, and may be utilized as
a novel treatment against corneal neovascularization and possibly
other angiogenesis-related disorders.
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